## Pharmacology Answer Key

1. b) The study of drugs and their effects on living systems
2. a) Pharmacokinetics
3. c) Pharmacodynamics
4. b) Absorption, Distribution, Metabolism, Excretion
5. a) Liver
6. c) Kidneys
7. b) Oral
8. d) Intravenous
9. a) Sublingual
10. c) Rectal
11. b) To reduce fever
12. a) To relieve pain
13. c) To reduce inflammation
14. b) To suppress cough
15. a) To thin mucus
16. c) To treat bacterial infections
17. b) To treat viral infections
18. a) To treat fungal infections
19. d) To treat parasitic infections
20. b) To treat cancer
21. c) To treat high blood pressure
22. a) To treat high cholesterol
23. b) To treat heart failure
24. d) To treat irregular heart rhythms
25. a) To treat blood clots
26. c) To treat diabetes
27. b) To treat thyroid disorders
28. a) To treat adrenal disorders
29. d) To treat growth hormone deficiency
30. b) To treat diabetes insipidus
31. c) To treat osteoporosis
32. a) To treat anemia
33. b) To stimulate white blood cell production
34. c) To treat allergies
35. a) To relieve nasal congestion
36. b) To suppress cough
37. c) To thin mucus
38. a) To treat asthma
39. b) To reduce inflammation in the airways
40. c) To prevent asthma attacks
41. a) To treat depression
42. b) To treat anxiety
43. c) To treat psychosis
44. d) To treat bipolar disorder
45. a) To treat insomnia
46. b) To treat seizures
47. c) To treat pain
48. d) To treat inflammation
49. a) To treat fever
50. b) To reduce blood clots
51. b) Inhibiting COX-1 and COX-2 enzymes, reducing prostaglandin synthesis
52. c) Blocking opioid receptors
53. a) Activating GABA-A receptors, increasing chloride influx and neuronal inhibition
54. b) Inhibiting serotonin and norepinephrine reuptake
55. c) Blocking dopamine D2 receptors
56. a) Blocking voltage-gated sodium channels
57. b) Increasing GABAergic neurotransmission
58. c) Inhibiting bacterial cell wall synthesis
59. a) Inhibiting viral replication
60. b) Disrupting fungal cell membranes
61. c) Inhibiting parasitic enzyme systems
62. a) Inhibiting DNA synthesis or function in cancer cells
63. b) Blocking angiotensin-converting enzyme, preventing angiotensin II formation and reducing aldosterone secretion
64. c) Blocking angiotensin II receptors
65. a) Blocking calcium channels, leading to vasodilation and reduced cardiac contractility
66. b) Blocking beta-adrenergic receptors, reducing heart rate and contractility
67. c) Increasing sodium and water excretion by inhibiting reabsorption in the renal tubules
68. a) Increasing sodium and water excretion by inhibiting reabsorption in the loop of Henle
69. b) Increasing sodium and water excretion by inhibiting reabsorption in the distal convoluted tubule
70. c) Increasing sodium and water excretion by inhibiting reabsorption in the collecting duct
71. a) Blocking alpha-1 adrenergic receptors, leading to vasodilation and reduced peripheral resistance
72. b) Stimulating alpha-2 adrenergic receptors in the brainstem, reducing sympathetic outflow
73. c) Relaxing arteriolar smooth muscle, leading to vasodilation and reduced peripheral resistance
74. b) Releasing nitric oxide, leading to vasodilation
75. a) Vasodilation, primarily of veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries
76. b) Blocking sodium channels
77. c) Blocking beta-adrenergic receptors
78. a) Prolonging the action potential and refractory period by blocking potassium channels
79. b) Blocking calcium channels
80. c) Increasing the force of myocardial contraction (positive inotropic effect) and slowing heart rate
81. a) Yellow-green halos around lights (visual disturbances)
82. b) Inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver
83. c) Gemfibrozil
84. a) Binding to bile acids in the intestine, preventing their reabsorption and increasing their excretion
85. b) Ezetimibe
86. c) Antiplatelet (prevention of blood clots)
87. b) Clopidogrel
88. a) Potentiating the action of antithrombin III, which inactivates thrombin and factor Xa
89. b) Enoxaparin
90. c) Inhibiting vitamin K epoxide reductase, thereby impairing the synthesis of vitamin K-dependent clotting factors
91. b) Vitamin K
92. a) Directly inhibiting thrombin
93. b) Rivaroxaban
94. c) To dissolve existing blood clots in conditions like acute myocardial infarction or ischemic stroke
95. a) Epoetin alfa
96. b) To stimulate the production of white blood cells (neutrophils) in patients with neutropenia
97. c) Blocking histamine H1 receptors, reducing allergic symptoms
98. a) Loratadine
99. b) To relieve nasal congestion by vasoconstriction
100. c) Dextromethorphan
101. b) Class II (e.g., propranolol, metoprolol)
102. c) Prolonging the action potential and refractory period by blocking potassium channels
103. d) Class IV (e.g., verapamil, diltiazem)
104. b) To increase the force of myocardial contraction (positive inotropic effect) and slow heart rate
105. b) Yellow-green halos around lights (visual disturbances)
106. b) Inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver
107. b) Gemfibrozil
108. b) Binding to bile acids in the intestine, preventing their reabsorption and increasing their excretion
109. b) Ezetimibe
110. c) Antiplatelet (prevention of blood clots)
111. b) Clopidogrel
112. b) Potentiating the action of antithrombin III, which inactivates thrombin and factor Xa
113. b) Enoxaparin
114. b) Inhibiting vitamin K epoxide reductase, thereby impairing the synthesis of vitamin K-dependent clotting factors
115. b) Vitamin K
116. b) Directly inhibiting thrombin
117. c) Rivaroxaban
118. b) To dissolve existing blood clots in conditions like acute myocardial infarction or ischemic stroke
119. c) Epoetin alfa
120. b) To stimulate the production of white blood cells (neutrophils) in patients with neutropenia
121. b) Blocking histamine H1 receptors, reducing allergic symptoms
122. b) Loratadine
123. b) To relieve nasal congestion by vasoconstriction
124. b) Dextromethorphan
125. b) Thinning respiratory secretions, making them easier to cough up
126. b) Acetylcysteine
127. b) To relax bronchial smooth muscle, widening the airways
128. b) Formoterol
129. b) Reducing inflammation in the airways
130. b) Montelukast
131. b) To facilitate the uptake of glucose from the blood into cells, lowering blood glucose levels
132. d) Insulin lispro (rapid-acting)
133. b) Stimulating insulin secretion from pancreatic beta cells
134. b) Metformin
135. c) Improving insulin sensitivity in muscle and adipose tissue by activating PPAR-gamma
136. b) DPP-4 inhibitors (e.g., sitagliptin)
137. b) Increasing glucose excretion in the urine by inhibiting sodium-glucose cotransporter 2 in the kidneys
138. c) Thyroxine (T4)
139. c) Levothyroxine (synthetic T4) replacement therapy
140. b) Methimazole
141. b) To increase blood calcium levels by stimulating bone resorption and calcium reabsorption in the kidneys
142. c) Alendronate
143. b) Treatment of growth hormone deficiency in children and adults
144. b) Antidiuretic hormone (ADH) / Vasopressin
145. b) Desmopressin (synthetic ADH) replacement therapy
146. b) Aldosterone
147. b) Replacement therapy for adrenal insufficiency (Addison's disease)
148. b) Spironolactone
149. b) Increasing the osmotic pressure of the glomerular filtrate, drawing water into the tubules and promoting diuresis
150. a) Acetazolamide
151. b) Treatment of hypertension and benign prostatic hyperplasia (BPH)
152. b) Clonidine
153. b) Relaxing arteriolar smooth muscle, leading to vasodilation and reduced peripheral resistance
154. b) Sodium nitroprusside
155. b) Vasodilation, primarily of veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries
156. a) Class I (e.g., lidocaine, procainamide)
157. b) Class II (e.g., propranolol, metoprolol)
158. c) Prolonging the action potential and refractory period by blocking potassium channels
159. d) Class IV (e.g., verapamil, diltiazem)
160. b) To increase the force of myocardial contraction (positive inotropic effect) and slow heart rate
161. b) Yellow-green halos around lights (visual disturbances)
162. b) Inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver
163. b) Gemfibrozil
164. b) Binding to bile acids in the intestine, preventing their reabsorption and increasing their excretion
165. b) Ezetimibe
166. c) Antiplatelet (prevention of blood clots)
167. b) Clopidogrel
168. b) Potentiating the action of antithrombin III, which inactivates thrombin and factor Xa
169. b) Enoxaparin
170. b) Inhibiting vitamin K epoxide reductase, thereby impairing the synthesis of vitamin K-dependent clotting factors
171. b) Vitamin K
172. b) Directly inhibiting thrombin
173. c) Rivaroxaban
174. b) To dissolve existing blood clots in conditions like acute myocardial infarction or ischemic stroke
175. c) Epoetin alfa
176. b) To stimulate the production of white blood cells (neutrophils) in patients with neutropenia
177. b) Blocking histamine H1 receptors, reducing allergic symptoms
178. b) Loratadine
179. b) To relieve nasal congestion by vasoconstriction
180. b) Dextromethorphan
181. b) Thinning respiratory secretions, making them easier to cough up
182. b) Acetylcysteine
183. b) To relax bronchial smooth muscle, widening the airways
184. b) Formoterol
185. b) Reducing inflammation in the airways
186. b) Montelukast
187. b) To facilitate the uptake of glucose from the blood into cells, lowering blood glucose levels
188. d) Insulin lispro (rapid-acting)
189. b) Stimulating insulin secretion from pancreatic beta cells
190. b) Metformin
191. c) Improving insulin sensitivity in muscle and adipose tissue by activating PPAR-gamma
192. b) DPP-4 inhibitors (e.g., sitagliptin)
193. b) Increasing glucose excretion in the urine by inhibiting sodium-glucose cotransporter 2 in the kidneys
194. c) Thyroxine (T4)
195. c) Levothyroxine (synthetic T4) replacement therapy
196. b) Methimazole
197. b) To increase blood calcium levels by stimulating bone resorption and calcium reabsorption in the kidneys
198. c) Alendronate
199. b) Treatment of growth hormone deficiency in children and adults
200. b) Antidiuretic hormone (ADH) / Vasopressin
201. b) Desmopressin (synthetic ADH) replacement therapy
202. b) Aldosterone
203. b) Replacement therapy for adrenal insufficiency (Addison's disease)
204. b) Spironolactone
205. b) Increasing the osmotic pressure of the glomerular filtrate, drawing water into the tubules and promoting diuresis
206. a) Acetazolamide
207. b) Treatment of hypertension and benign prostatic hyperplasia (BPH)
208. b) Clonidine
209. b) Relaxing arteriolar smooth muscle, leading to vasodilation and reduced peripheral resistance
210. b) Sodium nitroprusside
211. b) Vasodilation, primarily of veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries
212. a) Class I (e.g., lidocaine, procainamide)
213. b) Class II (e.g., propranolol, metoprolol)
214. c) Prolonging the action potential and refractory period by blocking potassium channels
215. d) Class IV (e.g., verapamil, diltiazem)
216. b) To increase the force of myocardial contraction (positive inotropic effect) and slow heart rate
217. b) Yellow-green halos around lights (visual disturbances)
218. b) Inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver
219. b) Gemfibrozil
220. b) Binding to bile acids in the intestine, preventing their reabsorption and increasing their excretion
221. b) Ezetimibe
222. c) Antiplatelet (prevention of blood clots)
223. b) Clopidogrel
224. b) Potentiating the action of antithrombin III, which inactivates thrombin and factor Xa
225. b) Enoxaparin
226. b) Inhibiting vitamin K epoxide reductase, thereby impairing the synthesis of vitamin K-dependent clotting factors
227. b) Vitamin K
228. b) Directly inhibiting thrombin
229. c) Rivaroxaban
230. b) To dissolve existing blood clots in conditions like acute myocardial infarction or ischemic stroke
231. c) Epoetin alfa
232. b) To stimulate the production of white blood cells (neutrophils) in patients with neutropenia
233. b) Blocking histamine H1 receptors, reducing allergic symptoms
234. b) Loratadine
235. b) To relieve nasal congestion by vasoconstriction
236. b) Dextromethorphan
237. b) Thinning respiratory secretions, making them easier to cough up
238. b) Acetylcysteine
239. b) To relax bronchial smooth muscle, widening the airways
240. b) Formoterol
241. b) Reducing inflammation in the airways
242. b) Montelukast
243. b) To facilitate the uptake of glucose from the blood into cells, lowering blood glucose levels
244. d) Insulin lispro (rapid-acting)
245. b) Stimulating insulin secretion from pancreatic beta cells
246. b) Metformin
247. c) Improving insulin sensitivity in muscle and adipose tissue by activating PPAR-gamma
248. b) DPP-4 inhibitors (e.g., sitagliptin)
249. b) Increasing glucose excretion in the urine by inhibiting sodium-glucose cotransporter 2 in the kidneys
250. c) Thyroxine (T4)
251. c) Levothyroxine (synthetic T4) replacement therapy
252. b) Methimazole
253. b) To increase blood calcium levels by stimulating bone resorption and calcium reabsorption in the kidneys
254. c) Alendronate
255. b) Treatment of growth hormone deficiency in children and adults
256. b) Antidiuretic hormone (ADH) / Vasopressin
257. b) Desmopressin (synthetic ADH) replacement therapy
258. b) Aldosterone
259. b) Replacement therapy for adrenal insufficiency (Addison's disease)
260. b) Spironolactone
261. b) Increasing the osmotic pressure of the glomerular filtrate, drawing water into the tubules and promoting diuresis
262. a) Acetazolamide
263. b) Treatment of hypertension and benign prostatic hyperplasia (BPH)
264. b) Clonidine
265. b) Relaxing arteriolar smooth muscle, leading to vasodilation and reduced peripheral resistance
266. b) Sodium nitroprusside
267. b) Vasodilation, primarily of veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries
268. a) Class I (e.g., lidocaine, procainamide)
269. b) Class II (e.g., propranolol, metoprolol)
270. c) Prolonging the action potential and refractory period by blocking potassium channels
271. d) Class IV (e.g., verapamil, diltiazem)
272. b) To increase the force of myocardial contraction (positive inotropic effect) and slow heart rate
273. b) Yellow-green halos around lights (visual disturbances)
274. b) Inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver
275. b) Gemfibrozil
276. b) Binding to bile acids in the intestine, preventing their reabsorption and increasing their excretion
277. b) Ezetimibe
278. c) Antiplatelet (prevention of blood clots)
279. b) Clopidogrel
280. b) Potentiating the action of antithrombin III, which inactivates thrombin and factor Xa
281. b) Enoxaparin
282. b) Inhibiting vitamin K epoxide reductase, thereby impairing the synthesis of vitamin K-dependent clotting factors
283. b) Vitamin K
284. b) Directly inhibiting thrombin
285. c) Rivaroxaban
286. b) To dissolve existing blood clots in conditions like acute myocardial infarction or ischemic stroke
287. c) Epoetin alfa
288. b) To stimulate the production of white blood cells (neutrophils) in patients with neutropenia
289. b) Blocking histamine H1 receptors, reducing allergic symptoms
290. b) Loratadine
291. b) To relieve nasal congestion by vasoconstriction
292. b) Dextromethorphan
293. b) Thinning respiratory secretions, making them easier to cough up
294. b) Acetylcysteine
295. b) To relax bronchial smooth muscle, widening the airways
296. b) Formoterol
297. b) Reducing inflammation in the airways
298. b) Montelukast
299. b) To facilitate the uptake of glucose from the blood into cells, lowering blood glucose levels
300. d) Insulin lispro (rapid-acting)
301. b) Stimulating insulin secretion from pancreatic beta cells
302. b) Metformin
303. c) Improving insulin sensitivity in muscle and adipose tissue by activating PPAR-gamma
304. b) DPP-4 inhibitors (e.g., sitagliptin)
305. b) Increasing glucose excretion in the urine by inhibiting sodium-glucose cotransporter 2 in the kidneys
306. c) Thyroxine (T4)
307. c) Levothyroxine (synthetic T4) replacement therapy
308. b) Methimazole
309. b) To increase blood calcium levels by stimulating bone resorption and calcium reabsorption in the kidneys
310. c) Alendronate
311. b) Treatment of growth hormone deficiency in children and adults
312. b) Antidiuretic hormone (ADH) / Vasopressin
313. b) Desmopressin (synthetic ADH) replacement therapy
314. b) Aldosterone
315. b) Replacement therapy for adrenal insufficiency (Addison's disease)
316. b) Spironolactone
317. b) Increasing the osmotic pressure of the glomerular filtrate, drawing water into the tubules and promoting diuresis
318. a) Acetazolamide
319. b) Treatment of hypertension and benign prostatic hyperplasia (BPH)
320. b) Clonidine
321. b) Relaxing arteriolar smooth muscle, leading to vasodilation and reduced peripheral resistance
322. b) Sodium nitroprusside
323. b) Vasodilation, primarily of veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries
324. a) Class I (e.g., lidocaine, procainamide)
325. b) Class II (e.g., propranolol, metoprolol)
326. c) Prolonging the action potential and refractory period by blocking potassium channels
327. d) Class IV (e.g., verapamil, diltiazem)
328. b) To increase the force of myocardial contraction (positive inotropic effect) and slow heart rate
329. b) Yellow-green halos around lights (visual disturbances)
330. b) Inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver
331. b) Gemfibrozil
332. b) Binding to bile acids in the intestine, preventing their reabsorption and increasing their excretion
333. b) Ezetimibe
334. c) Antiplatelet (prevention of blood clots)
335. b) Clopidogrel
336. b) Potentiating the action of antithrombin III, which inactivates thrombin and factor Xa
337. b) Enoxaparin
338. b) Inhibiting vitamin K epoxide reductase, thereby impairing the synthesis of vitamin K-dependent clotting factors
339. b) Vitamin K
340. b) Directly inhibiting thrombin
341. c) Rivaroxaban
342. b) To dissolve existing blood clots in conditions like acute myocardial infarction or ischemic stroke
343. c) Epoetin alfa
344. b) To stimulate the production of white blood cells (neutrophils) in patients with neutropenia
345. b) Blocking histamine H1 receptors, reducing allergic symptoms
346. b) Loratadine
347. b) To relieve nasal congestion by vasoconstriction
348. b) Dextromethorphan
349. b) Thinning respiratory secretions, making them easier to cough up
350. b) Acetylcysteine
351. b) To relax bronchial smooth muscle, widening the airways
352. b) Formoterol
353. b) Reducing inflammation in the airways
354. b) Montelukast
355. b) To facilitate the uptake of glucose from the blood into cells, lowering blood glucose levels
356. d) Insulin lispro (rapid-acting)
357. b) Stimulating insulin secretion from pancreatic beta cells
358. b) Metformin
359. c) Improving insulin sensitivity in muscle and adipose tissue by activating PPAR-gamma
360. b) DPP-4 inhibitors (e.g., sitagliptin)
361. b) Increasing glucose excretion in the urine by inhibiting sodium-glucose cotransporter 2 in the kidneys
362. c) Thyroxine (T4)
363. c) Levothyroxine (synthetic T4) replacement therapy
364. b) Methimazole
365. b) To increase blood calcium levels by stimulating bone resorption and calcium reabsorption in the kidneys
366. c) Alendronate
367. b) Treatment of growth hormone deficiency in children and adults
368. b) Antidiuretic hormone (ADH) / Vasopressin
369. b) Desmopressin (synthetic ADH) replacement therapy
370. b) Aldosterone
371. b) Replacement therapy for adrenal insufficiency (Addison's disease)
372. b) Spironolactone
373. b) Increasing the osmotic pressure of the glomerular filtrate, drawing water into the tubules and promoting diuresis
374. a) Acetazolamide
375. b) Treatment of hypertension and benign prostatic hyperplasia (BPH)
376. b) Clonidine
377. b) Relaxing arteriolar smooth muscle, leading to vasodilation and reduced peripheral resistance
378. b) Sodium nitroprusside
379. b) Vasodilation, primarily of veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries
380. a) Class I (e.g., lidocaine, procainamide)
381. b) Class II (e.g., propranolol, metoprolol)
382. c) Prolonging the action potential and refractory period by blocking potassium channels
383. d) Class IV (e.g., verapamil, diltiazem)
384. b) To increase the force of myocardial contraction (positive inotropic effect) and slow heart rate
385. b) Yellow-green halos around lights (visual disturbances)
386. b) Inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver
387. b) Gemfibrozil
388. b) Binding to bile acids in the intestine, preventing their reabsorption and increasing their excretion
389. b) Ezetimibe
390. c) Antiplatelet (prevention of blood clots)
391. b) Clopidogrel
392. b) Potentiating the action of antithrombin III, which inactivates thrombin and factor Xa
393. b) Enoxaparin
394. b) Inhibiting vitamin K epoxide reductase, thereby impairing the synthesis of vitamin K-dependent clotting factors
395. b) Vitamin K
396. b) Directly inhibiting thrombin
397. c) Rivaroxaban
398. b) To dissolve existing blood clots in conditions like acute myocardial infarction or ischemic stroke
399. c) Epoetin alfa
400. b) To stimulate the production of white blood cells (neutrophils) in patients with neutropenia
401. b) Blocking histamine H1 receptors, reducing allergic symptoms
402. b) Loratadine
403. b) To relieve nasal congestion by vasoconstriction
404. b) Dextromethorphan
405. b) Thinning respiratory secretions, making them easier to cough up
406. b) Acetylcysteine
407. b) To relax bronchial smooth muscle, widening the airways
408. b) Formoterol
409. b) Reducing inflammation in the airways
410. b) Montelukast
411. b) To facilitate the uptake of glucose from the blood into cells, lowering blood glucose levels
412. d) Insulin lispro (rapid-acting)
413. b) Stimulating insulin secretion from pancreatic beta cells
414. b) Metformin
415. c) Improving insulin sensitivity in muscle and adipose tissue by activating PPAR-gamma
416. b) DPP-4 inhibitors (e.g., sitagliptin)
417. b) Increasing glucose excretion in the urine by inhibiting sodium-glucose cotransporter 2 in the kidneys
418. c) Thyroxine (T4)
419. c) Levothyroxine (synthetic T4) replacement therapy
420. b) Methimazole
421. b) To increase blood calcium levels by stimulating bone resorption and calcium reabsorption in the kidneys
422. c) Alendronate
423. b) Treatment of growth hormone deficiency in children and adults
424. b) Antidiuretic hormone (ADH) / Vasopressin
425. b) Desmopressin (synthetic ADH) replacement therapy
426. b) Aldosterone
427. b) Replacement therapy for adrenal insufficiency (Addison's disease)
428. b) Spironolactone
429. b) Increasing the osmotic pressure of the glomerular filtrate, drawing water into the tubules and promoting diuresis
430. a) Acetazolamide
431. b) Treatment of hypertension and benign prostatic hyperplasia (BPH)
432. b) Clonidine
433. b) Relaxing arteriolar smooth muscle, leading to vasodilation and reduced peripheral resistance
434. b) Sodium nitroprusside
435. b) Vasodilation, primarily of veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries
436. a) Class I (e.g., lidocaine, procainamide)
437. b) Class II (e.g., propranolol, metoprolol)
438. c) Prolonging the action potential and refractory period by blocking potassium channels
439. d) Class IV (e.g., verapamil, diltiazem)
440. b) To increase the force of myocardial contraction (positive inotropic effect) and slow heart rate
441. b) Yellow-green halos around lights (visual disturbances)
442. b) Inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver
443. b) Gemfibrozil
444. b) Binding to bile acids in the intestine, preventing their reabsorption and increasing their excretion
445. b) Ezetimibe
446. c) Antiplatelet (prevention of blood clots)
447. b) Clopidogrel
448. b) Potentiating the action of antithrombin III, which inactivates thrombin and factor Xa
449. b) Enoxaparin
450. b) Inhibiting vitamin K epoxide reductase, thereby impairing the synthesis of vitamin K-dependent clotting factors
451. b) Vitamin K
452. b) Directly inhibiting thrombin
453. c) Rivaroxaban
454. b) To dissolve existing blood clots in conditions like acute myocardial infarction or ischemic stroke
455. c) Epoetin alfa
456. b) To stimulate the production of white blood cells (neutrophils) in patients with neutropenia
457. b) Blocking histamine H1 receptors, reducing allergic symptoms
458. b) Loratadine
459. b) To relieve nasal congestion by vasoconstriction
460. b) Dextromethorphan
461. b) Thinning respiratory secretions, making them easier to cough up
462. b) Acetylcysteine
463. b) To relax bronchial smooth muscle, widening the airways
464. b) Formoterol
465. b) Reducing inflammation in the airways
466. b) Montelukast
467. b) To facilitate the uptake of glucose from the blood into cells, lowering blood glucose levels
468. d) Insulin lispro (rapid-acting)
469. b) Stimulating insulin secretion from pancreatic beta cells
470. b) Metformin
471. c) Improving insulin sensitivity in muscle and adipose tissue by activating PPAR-gamma
472. b) DPP-4 inhibitors (e.g., sitagliptin)
473. b) Increasing glucose excretion in the urine by inhibiting sodium-glucose cotransporter 2 in the kidneys
474. c) Thyroxine (T4)
475. c) Levothyroxine (synthetic T4) replacement therapy
476. b) Methimazole
477. b) To increase blood calcium levels by stimulating bone resorption and calcium reabsorption in the kidneys
478. c) Alendronate
479. b) Treatment of growth hormone deficiency in children and adults
480. b) Antidiuretic hormone (ADH) / Vasopressin
481. b) Desmopressin (synthetic ADH) replacement therapy
482. b) Aldosterone
483. b) Replacement therapy for adrenal insufficiency (Addison's disease)
484. b) Spironolactone
485. b) Increasing the osmotic pressure of the glomerular filtrate, drawing water into the tubules and promoting diuresis
486. a) Acetazolamide
487. b) Treatment of hypertension and benign prostatic hyperplasia (BPH)
488. b) Clonidine
489. b) Relaxing arteriolar smooth muscle, leading to vasodilation and reduced peripheral resistance
490. b) Sodium nitroprusside
491. b) Vasodilation, primarily of veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries
492. a) Class I (e.g., lidocaine, procainamide)
493. b) Class II (e.g., propranolol, metoprolol)
494. c) Prolonging the action potential and refractory period by blocking potassium channels
495. d) Class IV (e.g., verapamil, diltiazem)
496. b) To increase the force of myocardial contraction (positive inotropic effect) and slow heart rate
497. b) Yellow-green halos around lights (visual disturbances)
498. b) Inhibiting the enzyme HMG-CoA reductase, which is involved in cholesterol synthesis in the liver
499. b) Gemfibrozil
500. b) Binding to bile acids in the intestine, preventing their reabsorption and increasing their excretion
501. b) Ezetimibe
502. c) Antiplatelet (prevention of blood clots)
503. b) Clopidogrel
504. b) Potentiating the action of antithrombin III, which inactivates thrombin and factor Xa
505. b) Enoxaparin
506. b) Inhibiting vitamin K epoxide reductase, thereby impairing the synthesis of vitamin K-dependent clotting factors
507. b) Vitamin K
508. b) Directly inhibiting thrombin
509. c) Rivaroxaban
510. b) To dissolve existing blood clots in conditions like acute myocardial infarction or ischemic stroke
511. c) Epoetin alfa
512. b) To stimulate the production of white blood cell production
513. b) Blocking histamine H1 receptors, reducing allergic symptoms
514. b) Loratadine
515. b) To relieve nasal congestion by vasoconstriction
516. b) Dextromethorphan
517. b) Thinning respiratory secretions, making them easier to cough up
518. b) Acetylcysteine
519. b) To relax bronchial smooth muscle, widening the airways
520. b) Formoterol
521. b) Reducing inflammation in the airways
522. b) Montelukast


